Please login to the form below

Not currently logged in

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

Treatment could be transformative for around 260 million people living with disease


GlaxoSmithKline has announced positive results from a phase 2a study of its Ionis-partnered antisense medicine for chronic hepatitis B virus (CHB) infection.

The drug, GSK3228836, showed marked reductions in hepatitis surface antigen (HBsAg) and hepatitis B virus DNA compared with placebo after four weeks treatment in people with CHB. The study participants were either on stable nucleoside, nucleotide analogue (NA) therapy or were naive to NA therapy.

Although hepatitis C has an effective range of treatments which can effectively cure most patients, hepatitis B remains difficult to treat and can cause cirrhosis, liver failure and liver cancer. Around 260 million people worldwide are currently living with CHB compared to around 70 million with hepatitis C.

Existing medications for CHB provide low levels of hepatitis B virus S antigen seroclearnace, which only suppress the virus, so need to be taken for life to maintain disease remission.

GSK3228836 uses antisense oligonucleotide technology to suppress the virus and viral proteins to functionally cure CHB. A functional cure means that although a virus is not completely eradicated, it is at a low enough level that it can be controlled by the immune system without medication.

GSK licensed GSK3228836 from Ionis last year, in a deal which saw it assume responsibility for all the development, regulatory and commercialisation costs associated with the treatment.

As part of the licensing deal, Ionis is set to receive fees and milestone payments of up to $262m, which included a $25m license fee. It is also eligible to receive tiered royalties in the low double digits on net sales.

“Chronic hepatitis B affects around 260 million people globally and, despite existing treatments, can lead to nearly 900,000 deaths per year due to liver failure and liver cancer,” said Christopher Corisco, senior vice president of development at GSK.

“We have observed promising early-stage results showing antiviral activity with our anti-sense oligonucleotide, a key investigational medicine in our growing infectious diseases portfolio. This marks a potential step forward toward the goal of assessing sustained functional cure for people with chronic hepatitis B,” he added.

GSK already has presence in the field with a hepatitis B vaccine, Ambirix, but GSK3228836 is a potential blockbuster in the making if it can effectively cure CHB.

Article by
Lucy Parsons

28th August 2020

From: Research



Subscribe to our email news alerts


Add my company
Research Partnership

Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...

Latest intelligence

The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...